Elutia (AZYO) Revenue & Revenue Breakdown
Elutia Revenue Highlights
Latest Revenue (Y)
$49.19M
Latest Revenue (Q)
$6.13M
Main Segment (Y)
Orthobiologics
Elutia Revenue by Period
Elutia Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2022-12-31 | $49.19M | 3.79% |
| 2021-12-31 | $47.39M | 11.03% |
| 2020-12-31 | $42.68M | -0.51% |
| 2019-12-31 | $42.90M | 9.90% |
| 2018-12-31 | $39.04M | - |
Elutia generated $49.19M in revenue during NA 2022, up 3.79% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Elutia Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2023-09-30 | $6.13M | -40.49% |
| 2023-06-30 | $10.30M | -21.10% |
| 2023-03-31 | $13.05M | 3.04% |
| 2022-12-31 | $12.66M | 2.23% |
| 2022-09-30 | $12.39M | -1.97% |
| 2022-06-30 | $12.64M | 9.94% |
| 2022-03-31 | $11.49M | 5.84% |
| 2021-12-31 | $10.86M | -5.43% |
| 2021-09-30 | $11.48M | -5.55% |
| 2021-06-30 | $12.16M | -5.62% |
| 2021-03-31 | $12.88M | 3.35% |
| 2020-12-31 | $12.47M | 5.88% |
| 2020-09-30 | $11.77M | 37.24% |
| 2020-06-30 | $8.58M | -13.02% |
| 2020-03-31 | $9.86M | -18.18% |
| 2019-12-31 | $12.05M | 8.22% |
| 2019-09-30 | $11.14M | - |
Elutia generated $6.13M in revenue during Q3 2023, up -40.49% compared to the previous quarter, and up 48.48% compared to the same period a year ago.
Elutia Revenue Breakdown
Elutia Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 |
|---|---|
| Cardiovascular | $7.28M |
| Orthobiologics | $25.34M |
| Women's Health | $7.47M |
Elutia's latest annual revenue breakdown by segment (product or service), as of Dec 22: Orthobiologics (63.20%), Women's Health (18.64%), and Cardiovascular (18.16%).
Quarterly Revenue by Product
| Product/Service | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Sep 20 |
|---|---|---|---|---|---|---|---|---|
| Cardiovascular | $1.75M | - | - | - | - | - | - | - |
| Orthobiologics | $6.66M | - | - | - | - | - | - | - |
| Women's Health | $2.29M | - | - | - | - | - | - | - |
| Non-Core Products | - | $3.44M | $3.59M | $3.35M | - | - | - | - |
| Core Products | - | $8.95M | $9.05M | $8.14M | $8.59M | $9.98M | $10.66M | $10.35M |
| Non Core Products | - | - | - | - | $2.90M | $2.18M | $2.22M | $1.43M |
Elutia's latest quarterly revenue breakdown by segment (product or service), as of Mar 23: Orthobiologics (62.22%), Women's Health (21.45%), and Cardiovascular (16.33%).
Elutia Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Sep 20 |
|---|---|---|---|---|---|---|---|---|
| Cardiovascular | $1.75M | - | - | - | - | - | - | - |
| Women's Health | $2.29M | - | - | - | - | - | - | - |
| Orthobiologics | $6.66M | - | - | - | - | - | - | - |
| Non-Core Products | - | $3.44M | $3.59M | $3.35M | - | - | - | - |
| Core Products | - | $8.95M | $9.05M | $8.14M | $8.59M | $9.98M | $10.66M | $10.35M |
| Non Core Products | - | - | - | - | $2.90M | $2.18M | $2.22M | $1.43M |
Elutia's latest quarterly revenue breakdown by geography, as of Mar 23: Orthobiologics (62.22%), Women's Health (21.45%), and Cardiovascular (16.33%).
Elutia Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AVNS | Avanos Medical | $673.30M | $171.70M |
| AORT | Artivion | $354.00M | $98.02M |
| ANIK | Anika Therapeutics | $166.66M | $41.92M |
| ESTA | Establishment Labs | $165.15M | $44.12M |
| AXGN | AxoGen | $159.01M | $47.91M |
| SRDX | Surmodics | $132.58M | $30.34M |
| SRGA | Surgalign | $81.98M | $16.75M |
| SGHT | Sight Sciences | $81.06M | $21.37M |
| IRIX | IRIDEX | $51.87M | $12.63M |
| AZYO | Elutia | $49.19M | $6.13M |
| LNSR | LENSAR | $42.16M | $10.59M |
| CVRX | CVRx | $39.30M | $11.81M |
| SSKN | STRATA Skin Sciences | $33.36M | $8.44M |
| INVO | INVO Bioscience | $3.02M | $1.58M |
| AIMD | Ainos | $122.11K | - |
| NXL | Nexalin | $110.75K | $26.84K |
| OFIX | Orthofix Medical | $100.00K | $198.62M |
| NVNO | enVVeno Medical | - | - |
AZYO Revenue FAQ
What is Elutia’s yearly revenue?
Elutia's yearly revenue for 2022 was $49.19M, representing an increase of 3.79% compared to 2021. The company's yearly revenue for 2021 was $47.39M, representing an increase of 11.03% compared to 2020. AZYO's yearly revenue for 2020 was $42.68M, representing a decrease of -0.51% compared to 2019.
What is Elutia’s quarterly revenue?
Elutia's quarterly revenue for Q3 2023 was $6.13M, a -40.49% decrease from the previous quarter (Q2 2023), and a -50.54% decrease year-over-year (Q3 2022). The company's quarterly revenue for Q2 2023 was $10.3M, a -21.10% decrease from the previous quarter (Q1 2023), and a -18.53% decrease year-over-year (Q2 2022). AZYO's quarterly revenue for Q1 2023 was $13.05M, a 3.04% increase from the previous quarter (Q4 2022), and a 13.53% increase year-over-year (Q1 2022).
What is Elutia’s revenue growth rate?
Elutia's revenue growth rate for the last 3 years (2020-2022) was 15.24%, and for the last 5 years (2018-2022) was 26.00%.
What are Elutia’s revenue streams?
Elutia's revenue streams in c 22 are Cardiovascular, Orthobiologics, and Women's Health. Cardiovascular generated $7.28M in revenue, accounting 18.16% of the company's total revenue Orthobiologics generated $25.34M in revenue, accounting 63.20% of the company's total revenue Women's Health generated $7.47M in revenue, accounting 18.64% of the company's total revenue
What is Elutia’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Elutia was Orthobiologics. This segment made a revenue of $25.34M, representing 63.20% of the company's total revenue.